A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

ABSTRACTEpithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that plays several roles in cancer biology. EpCAM is an attractive therapeutic target because of its expression in most solid tumors. However, targeting EpCAM has been challenging because it is also highly expressed in...

Full description

Bibliographic Details
Main Authors:	Gerhard Frey, Ana Paula G. Cugnetti, Haizhen Liu, Charles Xing, Christina Wheeler, Hwai Wen Chang, William J. Boyle, Jay M. Short
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Subjects:	Antibody engineering bispecific antibody conditionally active EpCAM protein engineering T-cell engager
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2322562

Similar Items

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer
by: Emily Maria Ploeg, et al.
Published: (2023-07-01)

mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth
by: Vita Golubovskaya, et al.
Published: (2023-05-01)

Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications
by: Guanjie Li, et al.
Published: (2022-06-01)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
by: Stefan Schönberger, et al.
Published: (2020-05-01)

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs
by: Joanna Macdonald, et al.
Published: (2018-01-01)

Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors
by: Min Wei, et al.
Published: (2022-11-01)

Destabilization of EpCAM dimer is associated with increased susceptibility towards cleavage by TACE
by: Tomaž Žagar, et al.
Published: (2021-05-01)

Evolution of Thyroglobulin Loop Kinetics in EpCAM
by: Serena H. Chen, et al.
Published: (2021-09-01)

A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG<sub>2a</sub>-f) Exerts Antitumor Activity in Xenograft Model
by: Teizo Asano, et al.
Published: (2022-11-01)

EpCAM as a novel therapeutic target for hepatocellular carcinoma
by: Vasanthakumar S, et al.
Published: (2017-07-01)

Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2
by: Ya-feng Lv, et al.
Published: (2023-12-01)

EpCAM (CD326) Regulates Intestinal Epithelial Integrity and Stem Cells via Rho-Associated Kinase
by: Takeshi Ouchi, et al.
Published: (2021-01-01)

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1
by: Anzhelika Vorobyeva, et al.
Published: (2020-05-01)

Dynamic Expression of EpCAM in Primary and Metastatic Lung Cancer Is Controlled by Both Genetic and Epigenetic Mechanisms
by: Yeting Cui, et al.
Published: (2022-08-01)

Targeted EpCAM-binding for the development of potent and effective anticancer proteins
by: Zhao Liu, et al.
Published: (2023-05-01)

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
by: Tianqi Xu, et al.
Published: (2021-08-01)

Current View on EpCAM Structural Biology
by: Aljaž Gaber, et al.
Published: (2020-05-01)

EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment
by: Chaoyu Zhang, et al.
Published: (2022-05-01)

Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis
by: Chi-Chiu Lee, et al.
Published: (2023-08-01)

Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1
by: Anzhelika Vorobyeva, et al.
Published: (2020-10-01)

Anti-EpCAM Functionalized I-131 Radiolabeled Biomimetic Nanocarrier Sodium/Iodide-Symporter-Mediated Breast-Cancer Treatment
by: Suphalak Khamruang Marshall, et al.
Published: (2022-06-01)

Matriptase Cleaves EpCAM and TROP2 in Keratinocytes, Destabilizing Both Proteins and Associated Claudins
by: Chuan-Jin Wu, et al.
Published: (2020-04-01)

Photo-functionalized TiO2 film for facile immobilization of EpCAM antibodies and efficient enrichment of circulating tumor cells
by: Huan Deng, et al.
Published: (2023-02-01)

A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression
by: Yu Hu, et al.
Published: (2019-07-01)

Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Salivary Gland Cancer: Correlation with the Biological Behavior
by: Ioanna Kalaitsidou, et al.
Published: (2023-08-01)

Leukocyte-Derived Extracellular Vesicles in Blood with and without EpCAM Enrichment
by: Afroditi Nanou, et al.
Published: (2019-08-01)

Amelioration of Congenital Tufting Enteropathy in EpCAM (TROP1)-Deficient Mice via Heterotopic Expression of TROP2 in Intestinal Epithelial Cells
by: Gaku Nakato, et al.
Published: (2020-08-01)

Targeting liver cancer stem cell through EpCAM therapy targeted with chemotherapy endorse enhanced progression in hepatocellular carcinoma
by: Vasanthakumar Sekar, et al.
Published: (2023-06-01)

Comprehensive analysis reveals dual biological function roles of EpCAM in kidney renal clear cell carcinoma
by: Mei Chen, et al.
Published: (2024-01-01)

An Intrabody against B-Cell Receptor-Associated Protein 31 (BAP31) Suppresses the Glycosylation of the Epithelial Cell-Adhesion Molecule (EpCAM) via Affecting the Formation of the Sec61-Translocon-Associated Protein (TRAP) Complex
by: Tianyi Wang, et al.
Published: (2023-09-01)

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model
by: Tianqi Xu, et al.
Published: (2023-02-01)

Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma
by: Mohammad Mashreghi, et al.
Published: (2020-05-01)

The Detection of Immunity against WT1 and SMAD4<sup>P130L</sup> of EpCAM<sup>+</sup> Cancer Cells in Malignant Pleural Effusion
by: Terutsugu Koya, et al.
Published: (2022-10-01)

Clinical Significance of Stem Cell Biomarkers EpCAM, LGR5 and LGR4 mRNA Levels in Lymph Nodes of Colon Cancer Patients
by: Manar AbdelMageed, et al.
Published: (2021-12-01)

Significant co-expression of putative cancer stem cell markers, EpCAM and CD166, correlates with tumor stage and invasive behavior in colorectal cancer
by: Elham Kalantari, et al.
Published: (2022-01-01)

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1
by: Sergey M. Deyev, et al.
Published: (2021-07-01)

A Novel Function for KLF4 in Modulating the De-Differentiation of EpCAM<sup>−</sup>/CD133<sup>−</sup> nonStem Cells into EpCAM<sup>+</sup>/CD133<sup>+</sup> Liver Cancer Stem Cells in HCC Cell Line HuH7
by: Zeynep Firtina Karagonlar, et al.
Published: (2020-05-01)

Expression of Cancer Stem Cell Markers EpCAM and CD90 Is Correlated with Anti- and Pro-Oncogenic EphA2 Signaling in Hepatocellular Carcinoma
by: Nobuhiko Asakura, et al.
Published: (2021-08-01)

CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy
by: Daan Linders, et al.
Published: (2021-03-01)

Functional Implications of the Dynamic Regulation of EpCAM during Epithelial-to-Mesenchymal Transition
by: Taylor C. Brown, et al.
Published: (2021-06-01)